Mice Model Market Worth $2.2 billion | MarketsandMarkets™

Mice Model Market in terms of revenue was estimated to be worth $1.5 billion in 2024 and is poised to reach $2.2 billion by 2029, growing at a CAGR of 8.1% from 2024 to 2029 according to a new report by MarketsandMarkets™. The rise in chronic diseases, such as cancer, diabetes, and cardiovascular disorders, and growing need for reliable and predictive animal models to facilitate drug discovery and development are the major driving factors of the mice model market. However, the presence of alternative research models, and recent guidelines of U.S.FDA on restriction animal models can hamper market growth.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1308&utm_source=Openpr&utm_campaign=Paid&utm_content=Referral

The CRISPR/Cas9 segment is expected to grow at a higher rate during the forecast period.

Based on technology, the mice model market has been segmented into CRISPR/Cas9, microinjection, embryonic stem cell injection, nuclear transfer, and other technologies. In 2023, the CRISPR/Cas9 segment accounted for the largest share of the mice model market is expected to grow at a higher growth rate during the forecast period of 2024-2029. CRISPR technology offers a cost-effective solution for generating genetically modified mice compared to traditional methods such as embryonic stem cell-based targeting.

The oncology segment accounted for the largest share of the therapeutic area segment in the mice model market in 2023.

Based on therapeutic area, the mice model market is segmented into oncology, neurology, metabolic diseases, immunology, cardiovascular diseases, and other diseases. In 2023, oncology accounted for the largest share of the mice model market. The expansion of the oncology mice model market is fueled by a surge in research funding dedicated to the advancement of personalized drug products for cancer treatment. For instance, the National Cancer Institute (NCI) allocated an estimated USD 6,467 million from its research budget, covering diverse disease areas such as AIDS, brain & CNS, and cancer.

The North America region accounted for the largest share of the mice model market in 2023.

The mice model market is segmented into North America, Europe, Asia Pacific (APAC), Latin America (LATAM), the Middle East, and Africa. The North America region is witnessing increasing investments and research activities in the field of drug discovery and development. The need for advanced therapies due to rising rate of cancer and other chronic diseases has contributed to growth of the mice model market.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=1308&utm_source=Openpr&utm_campaign=Paid&utm_content=Referral

Mice Model Market Dynamics:

Drivers:

High adoption of mice models in preclinical studies
Increasing demand for mouse clinical trials (MCTs)
Growing preference for personalized medicine in oncology
Advancements in genetic engineering
Restraints:

Introduction of 3D printed models
Ethical concerns and regulatory restrictions
Opportunities:

Low Utilization of CRISPR in biomedical research
Rising demand for disease-specific models
Challenge:

Development of alternative animal testing methods
Genetic & Phenotypic variability
Key Market Players of Mice Model Industry:

Key players in the mice model market Charles River Laboratories (US), Inotiv (US), THE JACKSON LABORATORY (US), GemPharmatech (China), Cyagen (US), Shanghai Model Organisms Center, Inc. (China), JSR Corporation (Japan), Biocytogen (China), TRANS GENIC INC. (Japan), Ozgene Pty Ltd. (Australia), Taconic Biosciences, Inc. (US), TransCure bioServices (France), Harbour BioMed (China), Marshall BioResources (US), genOway (France), Vivo Bio Tech Ltd. (India), ingenious targeting laboratory (US), Janvier Labs (France), Applied StemCell (US), Creative Animodel (US), JOINN Laboratories Co., Ltd. (China), Creative Biolabs (US), Crescendo Biologics (UK), Aragen Life Sciences (India), and PolyGene (Switzerland).

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side- 70% and Demand Side 30%
By Designation: C-level Executives - 55%, Director-level - 20%, and Others - 25%
By Region: North America -45%, Europe -20%, Asia-Pacific -20%, Latin America -10%, Middle East-3%, and Africa- 2%

Recent Developments of Mice Model Industry:

In December 2023, Biocytogen entered into a licensing agreement with Nuerocrine Biosciences. This agreement grants Neurocrine Biosciences the right to license selected antibodies for therapeutic product development, manufacturing, and commercialization for all uses worldwide.

In July 2022, GemPharmatech has entered into a strategic licensing agreement with Charles River Laboratories to distribute its next-generation NOD CRISPR Prkdc Il2r gamma (NCG) mouse lines in North America.

In April 2022, Inotiv acquired Histion, LLC. The acquisition is a strategic development that reflects the company's capabilities in expanding capabilities for surgical models and pathology services.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=1308&utm_source=Openpr&utm_campaign=Paid&utm_content=Referral

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insights: https://www.marketsandmarkets.com/ResearchInsight/mice-model-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/mice-model.asp

About MarketsandMarkets™:

MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

This release was published on openPR.